Ultra-LAMA, Ultra-LABA, Ultra-Inhaled Steroids? The Future has Landed;Ultra-LAMA, ultra-LABA, ultra-cortis? El futuro ya está aquí

Archivos de Bronconeumologia

Volumn 49, Issue 4, 2013, Pages 131-134

  Domingo, Christian ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; LONG ACTING DRUG; MUSCARINIC RECEPTOR BLOCKING AGENT; STEROID;

ARTICLE;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ALBUTEROL; ASTHMA; ETHANOLAMINES; FORECASTING; GLUCOCORTICOIDS; HUMANS; MUSCARINIC ANTAGONISTS; PREGNADIENEDIOLS; PREGNENEDIONES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SCOPOLAMINE DERIVATIVES;

EID: 84875812821     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/j.arbres.2012.11.011     Document Type: Article

References (63)

1. Gandevia B. Historical review of the use of parasympatholytic agents in the treatment of respiratory disorders. Postgrad Med J 1975, 51(Suppl 7):13-20.
2. Jackson M. Divine stramonium: the rise and fall of smoking for asthma. Med Hist 2010, 54:171-194.
3. Pearce N., Hensley M.J. Epidemiologic studies of beta agonists and asthma deaths. Epidemiol Rev 1998, 20:173-186.
4. Kesler B.S., Canning B.J. Regulation of baseline cholinergic tone in guineapig airway smooth muscle. J Physiol 1999, 518:843-855.
5. Canning B.J., Fischer A. Neural regulation of airway smooth muscle tone. Respir Physiol 2001, 125:113-127.
6. Barnes P.J. Muscarinic receptor subtypes in airways. Life Sci 1993, 52:521-527.
7. Reinheimer T., Mohlig T., Zimmermann S., Hohle K.D., Wessler I. Muscarinic control of histamine release from airways. Inhibitory M1-receptors in human bronchi but absence in rat trachea. Am J Respir Crit Care Med 2000, 162:534-538.
8. Maclagan J., Fryer A.D., Faulkner D. Identification of M1 muscarinic receptors in pulmonary sympathetic nerves in the guinea-pig by use of pirenzepine. Br J Pharmacol 1989, 97:499-505.
9. + channel activity in sympathetic neurons. Life Sci 2001, 68:2481-2487.
10. Struckmann N., Schwering S., Wiegand S. Role of muscarinic receptor subtypes in the constriction of peripheral airways: studies on receptor-deficient mice. Mol Pharmacol 2003, 64:1444-1451.
11. Richardson, Béland Nonadrenergic inhibitory nervous system in human airways. J Appl Physiol 1976, 41:764-771.
12. Skoogh B.E. Parasympathetic ganglia in the airways. Bull Eur Physiopathol Respir 1986, 22:143-147.
13. Carstairs J.R., Nimmo A.J., Barnes P.J. Autoradiographic visualization of betaadrenoceptor subtypes in human lung. Am Rev Respir Dis 1985, 132:541-547.
14. Ruffin R.E., McIntyre E.L., Latimer K.M., Ward H.E., Crockett A.J., Alpers J.H. Assessment of beta-adrenoceptor antagonists in asthmatic patients. Br J Clin Pharmacol 1982, 13(Suppl):325S-335S.
15. Lipson D.A. Tiotropium bromide. Int J Chron Obstruct Pulmon Dis 2006, 1:107-114.
16. Casaburi R., Briggs D.D., Donohue J.F., Serby C.W., Menjoge S.S., Witek T.J. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group. Chest 2000, 118:1294-1302.
17. Troosters T., Celli B., Lystig T., Kesten S., Mehra S., Tashkin D.P., et al. Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial. Eur Respir J 2010, 36:65-73.
18. Casaburi R., Kukafka D., Cooper C.B., Witek T.J., Kesten S. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 2005, 127:809-817.
19. Vogelmeier C., Banerji D. NVA237, a long-acting muscarinic antagonist, as an emerging therapy for chronic obstructive pulmonary disease. Adv Respir Dis 2011, 5:163-173.
20. Tashkin D.P., Celli B., Senn S., Burkhart D., Kesten S., Menjoge S., et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008, 359:1543-1554.
21. Miravitlles M., Anzueto A. Insights into interventions in managing COPD patients: lessons from the TORCH and UPLIFT studies. Int J Chron Obstruct Pulmon Dis 2009, 4:185-201.
22. Vogelmeier C., Hederer B., Glaab T., Schmidt H., Rutten-van Mölken M.P., Beeh K.M., et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011, 364:1093-1103.
23. Kerstjens H.A.M., Engel M., Dahl R., Paggiaro P., Beck E., Vandewalker M., et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med 2012, 367:1198-1207.
24. Wu K., Looby M., Pillai G., Pinault G., Drollman A.F., Pascoe S. Population pharmacodynamic model of the longitudinal FEV1 response to an inhaled longacting anti-muscarinic in COPD patients. J Pharmacokinet Pharmacodyn 2011, 38:105-119.
25. Casarosa P., Bouyssou T., Germeyer S., Schnapp A., Gantner F., Pieper M. Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs. J Pharmacol Exp Ther 2009, 330:660-668.
26. Villetti G., Bergamaschi M., Bassani F., Bolzoni P.T., Harrison S., Gigli P.M., et al. Pharmacological assessment of the duration of action of glycopyrrolate vs tiotropium and ipratropium in guinea-pig and human airways. Br J Pharmacol 2006, 148:291-298.
27. Verkindre C., Fukuchi Y., Flémale A., Takeda A., Overend T., Prasad N., et al. Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Respir Med 2010, 104:1482-1489.
28. D'Urzo A., Ferguson G.T., van Noord J.A., Hirata K., Martin C., Horton R., et al. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res 2011, 12:156.
29. Jansat J.M., Lamarca R., Garcia Gil E., Ferrer P. Safety and pharmacokinetics of single doses of aclidiniium bromide, a novel long-acting antimuscarinic in healthy subjects. Int J Clin Pharmacol Ther 2009, 47:460-468.
30. Cazzola M., Page C.P., Calzetta L., Matera M.G. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev 2012, 64:450-504.
31. Fuhr R., Magnussen H., Sarem K., Llovera A.R., Kirsten A.M., Falqués M., et al. Efficacy of aclidinium bromide 400μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD. Chest 2012, 141:745-752.
32. Kerwin E., Rennard S., Gelb A., Rekeda L., GarciaGil E., Caracta C. ACCORD COPD I: Improvements in nighttime symptoms and rescue medication use in COPD with twice-daily aclidinium bromide (Abstract). Eur Respir J 2011, 38:149s.
33. Donohue J.F., Anzueto A., Brooks J., Mehta R., Kalberg C., Crater G. A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD. Respir Med 2012, 106:970-979.
34. 2-adrenergic receptor from its partners determines signaling efficacy. J Biol Chem 2008, 283:24659-24672. 36.
35. Sturton R.G., Trifilieff A., Nicholson A.G., Barnes P.J. Pharmacological characterization of indacaterol, a novel once daily inhaled β2 adrenoceptor agonist, on small airways in human and rat precision-cut lung slices. J Pharmacol Exp Ther 2008, 324:270-275.
36. Rodrigo G.J., Neffen H. Comparison of indacaterol with tiotropium or twice-daily long-acting beta-agonists for stable copd: a systematic review. Chest 2012, 1104-1110. 142.
37. Naline E., Trifilieff A., Fairhurst R.A., Advenier C., Molimard M. Effect of indacaterol, a novel long acting β2-agonist, on isolated human bronchi. Eur Respir J 2007, 29:575-581.
38. Battram C., Charlton S.J., Cuenoud B., Dowling M.R., Fairhurst R.A., Farr D., et al. In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1- hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled β2 adrenoceptor. J Pharmacol Exp Ther 2006, 317:762-770.
39. Casarosa P., Kollak I., Kiechle T., Ostermann A., Schnapp A., Kiesling R., et al. Functional and biochemical rationales for the 24-hour-long duration of action of olodaterol. J Pharmacol Exp Ther 2011, 337:600-609.
40. Van Noord J.A., Smeets J.J., Drenth B.M., Rascher J., Pivovarova A., Hamilton A.L., et al. 24-Hour bronchodilation following a single dose of the novel β2-agonist olodaterol in COPD. Pulm Pharmacol Ther 2011, 24:666-672.
41. O'Byrne P.M., van der Linde J., Cockcroft D.W., Gauvreau G.M., Brannan J.D., Fitzgerald M., et al. Prolonged bronchoprotection against inhaled methacholine by inhaled BI 1744, a long-acting (2- agonist, in patients with mild asthma. J Allergy Clin Immunol 2009, 124:1217-1221.
42. Lötvall J., Bateman E.D., Bleecker E.R., Busse W.W., Woodcock A., Follows R., et al. 24 h duration of the novel LABA vilanterol trifenatate in asthma patients treated with ICSs. Eur Respir J 2012, 40:570-579.
43. Hanania N.A., Feldman G., Zachgo W., Shim J.J., Crim C., Sanford L., et al. The efficacy and safety of the novel long-acting β2 agonist vilanterol in COPD patients: a randomized placebo-controlled trial. Chest 2012, 142:119-127.
44. Bousquet J., d'Urzo A., Hebert J., Barraza C.H., Boulet L.P., Suárez-Chacón R., et al. Comparison of the efficacy and safety of mometasone furoate dry powder inhaler to budesonide Turbuhaler. Eur Respir J 2000, 16:808-816.
45. Smith C.L., Kreutner W. In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids. Arzneimittelforschung 1998, 48:956-960.
46. Corren J., Berkowitz R., Murray J., Prenner B. Comparison of once-daily mometasone furoate versus once-daily budesonide in patients with moderate persistent asthma. Int J Clin Pract 2003, 57:567-572.
47. Friedman H.S., Navaratnam P., McLaughlin J. Adherence and asthma control with propionate in adolescents and young adults with mild asthma. J Asthma 2010, 47:994-1000.
48. Skoner D.P., Meltzer E.O., Milgrom H., Stryszak P., Teper A., Staudinger H. Effects of inhaled mometasone furoate on growth velocity and adrenal function: a placebo-controlled trial in children 4-9 years old with mild persistent asthma. J Asthma 2011, 48:848-859.
49. Stoloff S.W., Kelly H.W. Updates on the use of inhaled corticosteroids in asthma. Curr Opin Allergy Clin Immunol 2011, 11:337-344.
50. Bateman E., Karpel J., Casale T., Wenzel S., Banerji D. Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma. Chest 2006, 129:1176-1187.
51. Dahl R. Ciclesonide for the treatment of asthma. Ther Clin Risk Manag 2006, 2:25-38.
52. Hübner M., Hochhaus G., Derendorf H. Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids. Immunol Allergy Clin N Am 2005, 25:469-488.
53. Derom E., van de Velde V., Marissens S., Engelstatter R., Vincken W., Pauwels R., et al. Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway responsiveness to adenosine 5'monophosphate in asthmatic patients Pulm. Phamacol Ther 2005, 18:328-336.
54. O'Connor B.J., Kilfeather S., Cheung D., Kafé H., Blagden M.D., Schlösser N., et al. Efficacy and safety of ciclesonide in patients with severe asthma: a 12-week, double-blind, randomized, parallel-group study with long-term (1-year) follow-up. Expert Opin Pharmacother 2010, 11:2791-2803.
55. Vermeulen J.H., Gyurkovits K., Rauer H., Engelstatter R. Randomized comparison of the efficacy and safety of ciclesonide and budesonide in adolescents with severe asthma. Respir Med 2007, 101:2182-2191.
56. Chapman K.R., Patel P., d'Urzo A.D., Alexander M., Mehra S., Oedekoven C., et al. Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma. Allergy 2005, 60:330-333.
57. Pearlman D.S., Berger W.E., Kerwin E., Laforce C., Kundu S., Banerji D. Once-daily ciclesonide improves lung function and is well tolerated by patients with mild-to-moderate persistent asthma. J Allergy Clin Immunol 2005, 116:1206-1212.
58. Cohen J., Douma W.R., ten Hacken N.H., Vonk J.M., Oudkerk M., Postma D.S. Ciclesonide improves measures of small airway involvement in asthma. Eur Respir 2008, 31:1213-1220.
59. Cazzola M., Calzetta L., Matera M.G. Beta(2)-adrenoceptor agonists: current and future direction. Br J Pharmacol 2011, 163:4-17.
60. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. NHLBI/WHO workshop report. National Institutes of Health, National Heart, Lung and Blood Institute. NIH publication number 95-3659. Disponible en: http://www.ginasthma.com [consultado 05 Feb 2013].
61. Guia Espanola para el Manejo del Asma (GEMA) 2009, GEMA, Disponible en: http://www.gemasma.com/descargas/GEMA%202009.pdf [consultado 5 Feb 2013].
62. Vestbo J. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. Eur Respir J 2004, 24:206-210. TORCH Study Group.
63. Guía de práctica clínica para el diagnóstico y tratamiento de pacientes con enfermedad pulmonar obstructiva crónica (EPOC) - Guía española de la EPOC (GesEPOC). Arch Bronconeumol 2012, 48(Supl 1):2-58. Grupo de Trabajo de GesEPOC.